359 related articles for article (PubMed ID: 29032004)
1. TNFR2: A Novel Target for Cancer Immunotherapy.
Vanamee ÉS; Faustman DL
Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
[TBL] [Abstract][Full Text] [Related]
3. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
4. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
[TBL] [Abstract][Full Text] [Related]
5. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
[TBL] [Abstract][Full Text] [Related]
6. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
[TBL] [Abstract][Full Text] [Related]
7. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
[TBL] [Abstract][Full Text] [Related]
8. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
9. TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.
Sheng Y; Li F; Qin Z
Front Immunol; 2018; 9():1170. PubMed ID: 29892300
[TBL] [Abstract][Full Text] [Related]
10. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
11. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.
Nagar M; Jacob-Hirsch J; Vernitsky H; Berkun Y; Ben-Horin S; Amariglio N; Bank I; Kloog Y; Rechavi G; Goldstein I
J Immunol; 2010 Apr; 184(7):3570-81. PubMed ID: 20181891
[TBL] [Abstract][Full Text] [Related]
12. The Roles of TNFR2 Signaling in Cancer Cells and the Tumor Microenvironment and the Potency of TNFR2 Targeted Therapy.
Takahashi H; Yoshimatsu G; Faustman DL
Cells; 2022 Jun; 11(12):. PubMed ID: 35741080
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
14. Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications.
Yang S; Wang J; Brand DD; Zheng SG
Front Immunol; 2018; 9():784. PubMed ID: 29725328
[TBL] [Abstract][Full Text] [Related]
15. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
Salomon BL; Leclerc M; Tosello J; Ronin E; Piaggio E; Cohen JL
Front Immunol; 2018; 9():444. PubMed ID: 29593717
[TBL] [Abstract][Full Text] [Related]
16. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
[TBL] [Abstract][Full Text] [Related]
17. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
[TBL] [Abstract][Full Text] [Related]
18. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells.
Twu YC; Gold MR; Teh HS
Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004
[TBL] [Abstract][Full Text] [Related]
19. TNFR2 ligation in human T regulatory cells enhances IL2-induced cell proliferation through the non-canonical NF-κB pathway.
Wang J; Ferreira R; Lu W; Farrow S; Downes K; Jermutus L; Minter R; Al-Lamki RS; Pober JS; Bradley JR
Sci Rep; 2018 Aug; 8(1):12079. PubMed ID: 30104686
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
